Skip Nav Destination
Issues
1 August 2016
-
Cover Image
Cover Image
The cover shows Fluor-18-deoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) scans of a patient with two metastatic lesions in the right lung. The image shows increased FDG uptake in the lesions prior to adoptive cell transfer therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL). For details, see the article by Andersen and colleagues on page 3734 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
Molecular Pathways
Review
Cancer Therapy: Clinical
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
Rikke Andersen; Marco Donia; Eva Ellebaek; Troels Holz Borch; Per Kongsted; Trine Zeeberg Iversen; Lisbet Rosenkrantz Hölmich; Helle Westergren Hendel; Özcan Met; Mads Hald Andersen; Per thor Straten; Inge Marie Svane
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Eric Padron; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Amy Dezern; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Marcio Andrade-Campos; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Kris Vaddi; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Peggy Scherle; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Qing Zhang; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Yan Ma; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Maria E. Balasis; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Sara Tinsley; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Hanadi Ramadan; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Cassandra Zimmerman; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; David P. Steensma; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Gail J. Roboz; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Jeffrey E. Lancet; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Alan F. List; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Mikkael A. Sekeres; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium; Rami S. Komrokji; on behalf of the Myelodysplastic Syndrome Clinical Research Consortium
Author Choice
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
José Baselga; Gail D. Lewis Phillips; Sunil Verma; Jungsil Ro; Jens Huober; Alice E. Guardino; Meghna K. Samant; Steve Olsen; Sanne L. de Haas; Mark D. Pegram
Author Choice
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli; Kirsten M. Timms; Julia Reid; Bryan Hennessy; Gordon B. Mills; Kristin C. Jensen; Zoltan Szallasi; William T. Barry; Eric P. Winer; Nadine M. Tung; Steven J. Isakoff; Paula D. Ryan; April Greene-Colozzi; Alexander Gutin; Zaina Sangale; Diana Iliev; Chris Neff; Victor Abkevich; Joshua T. Jones; Jerry S. Lanchbury; Anne-Renee Hartman; Judy E. Garber; James M. Ford; Daniel P. Silver; Andrea L. Richardson
Author Choice
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Pedro C. Rodriguez; Xitllaly Popa; Odeth Martínez; Silvia Mendoza; Eduardo Santiesteban; Tatiana Crespo; Rosa M. Amador; Ricardo Fleytas; Soraida C. Acosta; Yanine Otero; Gala N. Romero; Ana de la Torre; Mireysi Cala; Lina Arzuaga; Loisel Vello; Delmairis Reyes; Niurka Futiel; Teresa Sabates; Mauricio Catala; Yoanna I. Flores; Beatriz Garcia; Carmen Viada; Patricia Lorenzo-Luaces; Maria A. Marrero; Liuba Alonso; Jenelin Parra; Nadia Aguilera; Yaisel Pomares; Patricia Sierra; Gryssell Rodríguez; Zaima Mazorra; Agustin Lage; Tania Crombet; Elia Neninger
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
Daniel H. Sterman; Evan Alley; James P. Stevenson; Joseph Friedberg; Susan Metzger; Adri Recio; Edmund K. Moon; Andrew R. Haas; Anil Vachani; Sharyn I. Katz; Jing Sun; Daniel F. Heitjan; Wei-Ting Hwang; Leslie Litzky; Jennifer H. Yearley; Kay See Tan; Emmanouil Papasavvas; Paul Kennedy; Luis J. Montaner; Keith A. Cengel; Charles B. Simone, II; Melissa Culligan; Corey J. Langer; Steven M. Albelda
Personalized Medicine and Imaging
Author Choice
MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
Wendy Chang; Andrew S. Brohl; Rajesh Patidar; Sivasish Sindiri; Jack F. Shern; Jun S. Wei; Young K. Song; Marielle E. Yohe; Berkley Gryder; Shile Zhang; Kathleen A. Calzone; Nityashree Shivaprasad; Xinyu Wen; Thomas C. Badgett; Markku Miettinen; Kip R. Hartman; James C. League-Pascual; Toby N. Trahair; Brigitte C. Widemann; Melinda S. Merchant; Rosandra N. Kaplan; Jimmy C. Lin; Javed Khan
Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
Evgeny Yakirevich; Murray B. Resnick; Shamlal Mangray; Michael Wheeler; Cynthia L. Jackson; Kara A. Lombardo; Jeeyun Lee; Kyoung-Mee Kim; Anthony J. Gill; Kai Wang; Kyle Gowen; James Sun; Vincent A. Miller; Philip J. Stephens; Siraj M. Ali; Jeffrey S. Ross; Howard Safran
MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival
Kosuke Mima; Reiko Nishihara; Juhong Yang; Ruoxu Dou; Yohei Masugi; Yan Shi; Annacarolina da Silva; Yin Cao; Mingyang Song; Jonathan Nowak; Mancang Gu; Wanwan Li; Teppei Morikawa; Xuehong Zhang; Kana Wu; Hideo Baba; Edward L. Giovannucci; Jeffrey A. Meyerhardt; Andrew T. Chan; Charles S. Fuchs; Zhi Rong Qian; Shuji Ogino
Cancer Therapy: Preclinical
Author Choice
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma
Xueqing Lun; J. Connor Wells; Natalie Grinshtein; Jennifer C. King; Xiaoguang Hao; Ngoc-Ha Dang; Xiuling Wang; Ahmed Aman; David Uehling; Alessandro Datti; Jeffrey L. Wrana; Jacob C. Easaw; Artee Luchman; Samuel Weiss; J. Gregory Cairncross; David R. Kaplan; Stephen M. Robbins; Donna L. Senger
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
Keith W. Pratz; Brian D. Koh; Anand G. Patel; Karen S. Flatten; Weijie Poh; James G. Herman; Robert Dilley; Maria I. Harrell; B. Douglas Smith; Judith E. Karp; Elizabeth M. Swisher; Michael A. McDevitt; Scott H. Kaufmann
DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
Allison R. Hanaford; Tenley C. Archer; Antoinette Price; Ulf D. Kahlert; Jarek Maciaczyk; Guido Nikkhah; Jong Wook Kim; Tobias Ehrenberger; Paul A. Clemons; Vlado Dančík; Brinton Seashore-Ludlow; Vasanthi Viswanathan; Michelle L. Stewart; Matthew G. Rees; Alykhan Shamji; Stuart Schreiber; Ernest Fraenkel; Scott L. Pomeroy; Jill P. Mesirov; Pablo Tamayo; Charles G. Eberhart; Eric H. Raabe
Biology of Human Tumors
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Jason Madore; Dario Strbenac; Ricardo Vilain; Alexander M. Menzies; Jeen Y. H. Yang; John F. Thompson; Georgina V. Long; Graham J. Mann; Richard A. Scolyer; James S. Wilmott
Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Carlos Alfaro; Alvaro Teijeira; Carmen Oñate; Guiomar Pérez; Miguel F. Sanmamed; Maria Pilar Andueza; Diego Alignani; Sara Labiano; Arantza Azpilikueta; Alfonso Rodriguez-Paulete; Saray Garasa; Juan P. Fusco; Angela Aznar; Susana Inogés; Maria De Pizzol; Marcello Allegretti; Jose Medina-Echeverz; Pedro Berraondo; Jose L. Perez-Gracia; Ignacio Melero
Author Choice
Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Sandra M. Lopez; Alexander I. Agoulnik; Manqi Zhang; Leif E. Peterson; Egla Suarez; Gregory A. Gandarillas; Anna Frolov; Rile Li; Kimal Rajapakshe; Christian Coarfa; Michael M. Ittmann; Nancy L. Weigel; Irina U. Agoulnik
Author Choice
FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Shunrong Ji; Yi Qin; Chen Liang; Run Huang; Si Shi; Jiang Liu; Kaizhou Jin; Dingkong Liang; Wenyan Xu; Bo Zhang; Liang Liu; Chen Liu; Jin Xu; Quanxing Ni; Paul J. Chiao; Min Li; Xianjun Yu
Author Choice
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Paolo Bossi; Cristiana Bergamini; Marco Siano; Maria Cossu Rocca; Andrea P. Sponghini; Federica Favales; Marco Giannoccaro; Edoardo Marchesi; Barbara Cortelazzi; Federica Perrone; Silvana Pilotti; Laura D. Locati; Lisa Licitra; Silvana Canevari; Loris De Cecco
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds